<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="pds70160" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1557</journal-id><journal-id journal-id-type="publisher-id">PDS</journal-id><journal-title-group><journal-title>Pharmacoepidemiology and Drug Safety</journal-title></journal-title-group><issn pub-type="ppub">1053-8569</issn><issn pub-type="epub">1099-1557</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Chichester, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40393773</article-id><article-id pub-id-type="pmc">PMC12092166</article-id><article-id pub-id-type="doi">10.1002/pds.70160</article-id><article-id pub-id-type="publisher-id">PDS70160</article-id><article-id pub-id-type="other">PDS-24-0606.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Obtaining Valid Compatibility Intervals for Sequence Symmetry Analyses Utilizing Active Comparators: A Simulation Study</article-title></title-group><contrib-group><contrib id="pds70160-cr-0001" contrib-type="author" corresp="yes"><name><surname>Rahbek</surname><given-names>Martin Torp</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7506-3426</contrib-id><xref rid="pds70160-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>mrahbek@health.sdu.dk</email></address></contrib><contrib id="pds70160-cr-0002" contrib-type="author"><name><surname>Hallas</surname><given-names>Jesper</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8097-8708</contrib-id><xref rid="pds70160-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pds70160-cr-0003" contrib-type="author"><name><surname>Lund</surname><given-names>Lars Christian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8651-6072</contrib-id><xref rid="pds70160-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="pds70160-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Clinical Pharmacology, Pharmacy and Environmental Medicine</named-content>
<institution>University of Southern Denmark</institution>
<city>Odense</city>
<country country="DK">Denmark</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Martin Torp Rahbek (<email>mrahbek@health.sdu.dk</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>34</volume><issue seq="30">6</issue><issue-id pub-id-type="doi">10.1002/pds.v34.6</issue-id><elocation-id>e70160</elocation-id><history>
<date date-type="rev-recd"><day>27</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>28</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>01</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons, Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Pharmacoepidemiology and Drug Safety</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PDS-34-e70160.pdf"/><abstract><title>ABSTRACT</title><sec id="pds70160-sec-0001"><title>Purpose</title><p>To compare different methods of estimating 95% compatibility intervals (CIs) for the sequence ratio (SR) when performing a sequence symmetry analysis using an active comparator to reduce the risk of time&#x02010;varying confounding.</p></sec><sec id="pds70160-sec-0002"><title>Methods</title><p>We conducted a simulation study, where we simulated drug&#x02010;outcome and outcome&#x02010;drug sequences for a drug of interest and a comparator drug using the binomial distribution and obtained active comparator SRs and 95% CIs. We simulated scenarios with sample sizes between 5 and 50 observed sequences for each SR, which could take values of 0.5, 1.0, or 2.0, yielding 276 scenarios that were replicated 5000 times. For each replication, we calculated 95% CIs using current recommendations based on exact CIs, the Woolf logit, Baptista&#x02010;Pike mid&#x02010;<italic toggle="no">p</italic>, and Miettinen&#x02013;Nurminen score estimator and calculated coverage for each scenario.</p></sec><sec id="pds70160-sec-0003"><title>Results</title><p>All interval estimators provided acceptable coverage when sample sizes exceeded 15, except for the current recommendation, the exact Clopper&#x02013;Pearson interval. The Miettinen&#x02010;Nurminen score (coverage 0.951) and Baptista&#x02013;Pike mid&#x02010;<italic toggle="no">p</italic> interval (coverage 0.955) offered more accurate coverage than other methods. The largest divergence from 0.95 was observed for the current recommendations (coverage 0.979).</p></sec><sec id="pds70160-sec-0004"><title>Conclusions</title><p>The Miettinen&#x02013;Nurminen score estimator provided the most accurate coverage for 95% CIs of active comparator SRs, especially with low sample sizes. Therefore, we recommend using the Miettinen&#x02013;Nurminen score estimator for active comparator SRs.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pds70160-kwd-0001">active comparator</kwd><kwd id="pds70160-kwd-0002">compatibility intervals</kwd><kwd id="pds70160-kwd-0003">sequence symmetry analysis</kwd><kwd id="pds70160-kwd-0004">simulation study</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="4"/><word-count count="2000"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:20.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pds70160-ntgp-0001"><fn fn-type="funding" id="pds70160-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="pds70160-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="pds70160-blkfxd-5001"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="pds70160-list-8001"><list-item id="pds70160-li-7001"><p>Using an active comparator in sequence symmetry analysis reduces bias from confounding by indication.</p></list-item><list-item id="pds70160-li-6002"><p>The optimal estimator for calculating 95% compatibility intervals for active comparator sequence ratios is not known.</p></list-item><list-item id="pds70160-li-5003"><p>The Miettinen&#x02010;Nurminen score estimator achieved the most accurate 95% compatibility interval coverage of the tested estimators.</p></list-item><list-item id="pds70160-li-4004"><p>The Miettinen&#x02010;Nurminen score estimator provides the most accurate coverage, particularly in scenarios with low sample sizes.</p></list-item><list-item id="pds70160-li-3005"><p>The currently recommended method for estimating compatibility intervals, showed poorer performance than other of the tested methods.</p></list-item></list>
</p></boxed-text>
</p><sec id="pds70160-sec-1005"><label>1</label><title>Purpose</title><p>The sequence symmetry analysis is a self&#x02010;controlled design that is robust to time&#x02010;invariant confounding and has mainly been used for the detection of drug&#x02010;safety signals in large healthcare databases [<xref rid="pds70160-bib-0001" ref-type="bibr">1</xref>, <xref rid="pds70160-bib-0002" ref-type="bibr">2</xref>]. The effect estimate obtained from the sequence symmetry analysis is the sequence ratio (SR), which is an estimate of the incidence rate ratio that would have arisen from the underlying cohort study [<xref rid="pds70160-bib-0003" ref-type="bibr">3</xref>]. The SR is calculated as the number of exposure&#x02010;to&#x02010;outcome sequences divided by the number of outcome&#x02010;to&#x02010;exposure sequences. Valid compatibility intervals (CIs) [<xref rid="pds70160-bib-0004" ref-type="bibr">4</xref>] for the SR can be estimated based on a number of different distributions, including the normal, binomial, and beta distributions [<xref rid="pds70160-bib-0005" ref-type="bibr">5</xref>]. Like other self&#x02010;controlled designs, the sequence symmetry analysis is vulnerable to time&#x02010;varying confounding, including confounding by indication. This bias can be minimized by applying an active comparator to the design [<xref rid="pds70160-bib-0006" ref-type="bibr">6</xref>]. The resulting effect estimate is the active comparator SR and is calculated as the SR for the medication of interest divided by the SR for the comparator drug. Corresponding CIs have been recommended to be calculated based on the variance of the log&#x02010;difference between the two SRs being equal to the sum of their variances [<xref rid="pds70160-bib-0007" ref-type="bibr">7</xref>]. The proposed method assumes that the variance follows a normal distribution, which may not be the case when the sample size is low.</p><p>Summation of variances obtained from non&#x02010;normally distributed CIs may yield CIs with suboptimal coverage. Fortunately, other methods for interval estimation exist. If we consider the SR as the odds of an exposure&#x02010;to&#x02010;outcome sequence compared to the opposite sequence, then the active comparator SR would have the properties of an odds ratio. Previous literature has examined different methods of estimating CIs for odds ratios [<xref rid="pds70160-bib-0008" ref-type="bibr">8</xref>], but these have not been evaluated with SRs in mind. Therefore, we aimed to compare&#x02014;in a simulation study&#x02014;CIs for active comparator SRs derived according to first recommendations [<xref rid="pds70160-bib-0006" ref-type="bibr">6</xref>] with those derived from other methods.</p></sec><sec sec-type="methods" id="pds70160-sec-0006"><label>2</label><title>Methods</title><p>We conducted a simulation study, where we simulated the number of observed drug&#x02010;outcome and outcome&#x02010;drug sequences for a drug of interest and a comparator drug using the binomial distribution. Estimates of interest were the active comparator SR and the upper and lower bounds of the 95% CI and the resulting coverage.</p><sec id="pds70160-sec-0007"><label>2.1</label><title>Data Generating Mechanism</title><p>We simulated a range of different scenarios where we varied the observed number of sequences for each drug and the true values of the SR for each drug. The number of sequences was between 5 and 50 with true SRs of 0.5, 1 and 2, yielding 276 different scenarios (46 number of sequences &#x000d7;&#x02009;6 unique combinations of true SRs) each simulated 5000 times. In each replication, the number of observed exposure&#x02010;to&#x02010;outcome sequences for each drug was drawn from the binomial distribution with a given number of trials&#x02014;sequences&#x02014;and a probability corresponding to <mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mtext>true</mml:mtext></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mtext>true</mml:mtext></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math>.</p></sec><sec id="pds70160-sec-0008"><label>2.2</label><title>Estimand</title><p>The estimands of interest in this simulation study are the upper and lower bounds of the 95% CI for the ratio between the SR for the drug of interest and the SR for the comparator drug.</p></sec><sec id="pds70160-sec-0009"><label>2.3</label><title>Estimators</title><p>We tested several methods to estimate the bounds of the 95% CIs for the active comparator SR. First, we estimated intervals as outlined in the original description of active comparators in Self&#x02010;Controlled designs [<xref rid="pds70160-bib-0006" ref-type="bibr">6</xref>]. We calculated the SR for each drug and obtained 95% CIs. Then, we calculated the individual variance based on the limits of the CI (Appendix&#x000a0;<xref rid="pds70160-app-0001" ref-type="app">1</xref>). Finally, we summarized the variance for the two component SRs and calculated limits for the resulting CI based on the normal distribution (Appendix&#x000a0;<xref rid="pds70160-app-0002" ref-type="app">2</xref>). We tested this method with three different types of CIs for the individual SRs: the Agresti&#x02013;Coull interval, the Clopper&#x02013;Pearson interval, and a posterior interval based on Jeffrey's noninformative prior [<xref rid="pds70160-bib-0005" ref-type="bibr">5</xref>]. Second, we calculated 95% CIs that were directly based on the number of observed sequences for each drug. For this, we tested the Woolf logit (Appendix&#x000a0;<xref rid="pds70160-app-0003" ref-type="app">3</xref>) [<xref rid="pds70160-bib-0009" ref-type="bibr">9</xref>], the Baptista&#x02013;Pike mid&#x02010;<italic toggle="yes">p</italic> interval [<xref rid="pds70160-bib-0010" ref-type="bibr">10</xref>], and the Miettinen&#x02013;Nurminen score [<xref rid="pds70160-bib-0011" ref-type="bibr">11</xref>].</p></sec><sec id="pds70160-sec-0010"><label>2.4</label><title>Performance Measures</title><p>For each scenario and estimator, we calculated the observed coverage, Monte&#x02013;Carlo standard error [<xref rid="pds70160-bib-0012" ref-type="bibr">12</xref>] and corresponding divergence from the desired 0.95 coverage across all 5000 replications. We also calculated the overall coverage and divergence across all scenarios and replications. Here, coverage refers to the proportion of times that the true point estimate lies within the estimated CI across repeated samples. The divergence measures the deviation of the observed coverage from the desired coverage level (e.g., 0.95). A lower divergence indicates more accurate coverage.</p><p>Simulations were conducted using R version 4.3.3 [<xref rid="pds70160-bib-0013" ref-type="bibr">13</xref>]. We used relevant functions from the sasLM package [<xref rid="pds70160-bib-0014" ref-type="bibr">14</xref>] to calculate the Miettinen&#x02013;Nurminen score intervals and the ORCI package [<xref rid="pds70160-bib-0015" ref-type="bibr">15</xref>] to calculate Baptista&#x02013;Pike mid&#x02010;<italic toggle="yes">p</italic> intervals. The source code used to conduct these analyses is available from <ext-link xlink:href="https://gitlab.sdu.dk/lclund/active-comparator-sr-ci/" ext-link-type="uri">https://gitlab.sdu.dk/lclund/active&#x02010;comparator&#x02010;sr&#x02010;ci/</ext-link>.</p></sec></sec><sec sec-type="results" id="pds70160-sec-0011"><label>3</label><title>Results</title><p>All interval estimators yielded CIs with acceptable coverage when sample sizes exceeded 15, except for the exact Clopper&#x02010;Pearson intervals (Figure&#x000a0;<xref rid="pds70160-fig-0001" ref-type="fig">1</xref>). When comparing the coverage and divergence from the desired coverage across all scenarios, we found that the MiettinenvNurminen score (coverage 0.951) and Baptista&#x02013;Pike mid&#x02010;<italic toggle="yes">p</italic> interval (coverage 0.955) provided more accurate coverage than the other methods. The largest divergence was observed for the Wald method based on Clopper&#x02013;Pearson intervals (coverage 0.979) (Table&#x000a0;<xref rid="pds70160-tbl-0001" ref-type="table">1</xref>). We observed similar patterns when analyzing each scenario separately (Table&#x000a0;<xref rid="pds70160-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><fig position="float" fig-type="FIGURE" id="pds70160-fig-0001"><label>FIGURE 1</label><caption><p>Observed coverage for interval estimators across all scenarios. <italic toggle="yes">X</italic>&#x02010;axis indicates the sample size, the <italic toggle="yes">y</italic>&#x02010;axis the observed coverage. Plots are grouped in a matrix, with columns indicating the sequence ratio of the drug of interest (0.5, 1, and 2), and rows indicating the comparator sequence ratio (0.5, 1, 2). The left panel shows the results for interval estimators based on pooled variance of interval estimators derived separately for active substance and comparator. The right panel shows interval estimators based on the observed counts directly, without intermediate computation of interval estimators for active substance and comparator.</p></caption><graphic xlink:href="PDS-34-e70160-g001" position="anchor" id="jats-graphic-1"/></fig><table-wrap position="float" id="pds70160-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Divergence from the desired 0.95 coverage for each estimator, coverage, and Monte&#x02013;Carlo standard error across all combinations of sample size, sequence ratio, and comparator sequence ratio.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Estimator</th><th align="center" valign="bottom" rowspan="1" colspan="1">Divergence</th><th align="center" valign="bottom" rowspan="1" colspan="1">Coverage</th><th align="center" valign="bottom" rowspan="1" colspan="1">MCSE</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Miettinen&#x02013;Nurminen</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.951</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baptista&#x02013;Pike mid&#x02010;<italic toggle="yes">p</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td><td align="center" valign="top" rowspan="1" colspan="1">0.955</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jeffrey's sum</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">0.944</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Agresti&#x02013;Coull sum</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">0.957</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Woolf logit</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td><td align="center" valign="top" rowspan="1" colspan="1">0.957</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clopper&#x02013;Pearson sum</td><td align="center" valign="top" rowspan="1" colspan="1">0.029</td><td align="center" valign="top" rowspan="1" colspan="1">0.979</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot id="pds70160-ntgp-0002"><fn id="pds70160-note-0002"><p>Abbreviation: MCSE, Monte&#x02013;Carlo standard error.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions" id="pds70160-sec-0012"><label>4</label><title>Conclusions</title><p>In this simulation study of a sequence symmetry analysis, we found that the 95% CIs for the active comparator SR based on the Miettinen&#x02013;Nurminen score estimator provided the most accurate coverage. The previously recommended methods for estimating CIs or active comparator SRs assume that the variance of the SR for each separate drug is normally distributed, which is not always the case. The Miettunen&#x02010;Nurminen intervals are less conservative, especially when the total number of sequences is low. The previously proposed method of deriving CIs from the sum of the variances of the component SRs was clearly inferior, regardless of the interval estimator used for the individual SRs. We recommend the use of the Miettinen&#x02010;Nurminen score estimator for future active comparator SSA studies to ensure the estimation of CIs with the desired coverage. This ensures that SRs are classified correctly according to statistical significance, which is common practice in hypothesis&#x02010;generating studies.</p></sec><sec sec-type="COI-statement" id="pds70160-sec-0013"><title>Conflicts of Interest</title><p>Martin Torp Rahbek and Lars Christian Lund report no conflicts of interest. Jesper Hallas reports participation in post&#x02010;authorization safety studies funded by Novo Nordisk with money paid to his employer and with no personal fees involved.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pds70160-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Data S1.</bold> Supporting Information.</p></caption><media xlink:href="PDS-34-e70160-s001.docx"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="pds70160-bibl-0001"><title>References</title><ref id="pds70160-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="pds70160-cit-0001">
<string-name>
<given-names>J.</given-names>
<surname>Hallas</surname>
</string-name>, &#x0201c;<article-title>Evidence of Depression Provoked by Cardiovascular Medication: A Prescription Sequence Symmetry Analysis</article-title>,&#x0201d; <source>Epidemiology</source>
<volume>7</volume>, no. <issue>5</issue> (<year>1996</year>): <fpage>478</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">8862977</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="pds70160-cit-0002">
<string-name>
<given-names>J.</given-names>
<surname>Hallas</surname>
</string-name>, <string-name>
<given-names>S. V.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Gagne</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Schneeweiss</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Pratt</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Potteg&#x000e5;rd</surname>
</string-name>, &#x0201c;<article-title>Hypothesis&#x02010;Free Screening of Large Administrative Databases for Unsuspected Drug&#x02010;Outcome Associations</article-title>,&#x0201d; <source>European Journal of Epidemiology</source>
<volume>33</volume>, no. <issue>6</issue> (<year>2018</year>): <fpage>545</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">29605890</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="pds70160-cit-0003">
<string-name>
<given-names>T.</given-names>
<surname>Delvin</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Egsgaard</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Hallas</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Kildegaard</surname>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Lund</surname>
</string-name>, and <string-name>
<given-names>M. T.</given-names>
<surname>Rahbek</surname>
</string-name>, &#x0201c;<article-title>Is the Sequence Ratio an Unbiased Estimate of the Incidence Rate Ratio? A Simulation Study</article-title>,&#x0201d; <source>Pharmacoepidemiology and Drug Safety</source>
<volume>33</volume>, no. <issue>3</issue> (<year>2024</year>): <elocation-id>e5774</elocation-id>.<pub-id pub-id-type="pmid">38450934</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="pds70160-cit-0004">
<string-name>
<given-names>Z.</given-names>
<surname>Rafi</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Greenland</surname>
</string-name>, &#x0201c;<article-title>Semantic and Cognitive Tools to Aid Statistical Science: Replace Confidence and Significance by Compatibility and Surprise</article-title>,&#x0201d; <source>BMC Medical Research Methodology</source>
<volume>20</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>244</fpage>.<pub-id pub-id-type="pmid">32998683</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="pds70160-cit-0005">
<string-name>
<given-names>L. C.</given-names>
<surname>Lund</surname>
</string-name> and <string-name>
<given-names>J.</given-names>
<surname>Hallas</surname>
</string-name>, &#x0201c;<article-title>Recommendations on the Calculation of Confidence Intervals for Sequence Symmetry Analyses</article-title>,&#x0201d; <source>Pharmacoepidemiology and Drug Safety</source>
<volume>32</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>392</fpage>&#x02013;<lpage>394</lpage>.<pub-id pub-id-type="pmid">36448210</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="pds70160-cit-0006">
<string-name>
<given-names>J.</given-names>
<surname>Hallas</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Whitaker</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Delaney</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Cadarette</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Pratt</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Maclure</surname>
</string-name>, &#x0201c;<article-title>The Use of Active Comparators in Self&#x02010;Controlled Designs</article-title>,&#x0201d; <source>American Journal of Epidemiology</source>
<volume>190</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>2181</fpage>&#x02013;<lpage>2187</lpage>.<pub-id pub-id-type="pmid">33861309</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0007"><label>7</label><mixed-citation publication-type="book" id="pds70160-cit-0007">
<string-name>
<given-names>K.</given-names>
<surname>Sterne</surname>
</string-name>, <source>Essential Medical Statistics</source> (<publisher-name>John Wiley &#x00026; Sons</publisher-name>, <year>2003</year>).</mixed-citation></ref><ref id="pds70160-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="pds70160-cit-0008">
<string-name>
<given-names>M. W.</given-names>
<surname>Fagerland</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Lydersen</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Laake</surname>
</string-name>, &#x0201c;<article-title>Recommended Confidence Intervals for Two Independent Binomial Proportions</article-title>,&#x0201d; <source>Statistical Methods in Medical Research</source>
<volume>24</volume>, no. <issue>2</issue> (<year>2015</year>): <fpage>224</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">21996567</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="pds70160-cit-0009">
<string-name>
<given-names>B.</given-names>
<surname>Woolf</surname>
</string-name>, &#x0201c;<article-title>On Estimating the Relation Between Blood Group and Disease</article-title>,&#x0201d; <source>Annals of Human Genetics</source>
<volume>19</volume>, no. <issue>4</issue> (<year>1955</year>): <fpage>251</fpage>&#x02013;<lpage>253</lpage>.<pub-id pub-id-type="pmid">14388528</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="pds70160-cit-0010">
<string-name>
<given-names>M. W.</given-names>
<surname>Fagerland</surname>
</string-name>, &#x0201c;<article-title>Exact and Mid&#x02010;p Confidence Intervals for the Odds Ratio</article-title>,&#x0201d; <source>Stata Journal</source>
<volume>12</volume>, no. <issue>3</issue> (<year>2012</year>): <fpage>505</fpage>&#x02013;<lpage>514</lpage>.</mixed-citation></ref><ref id="pds70160-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="pds70160-cit-0011">
<string-name>
<given-names>O.</given-names>
<surname>Miettinen</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Nurminen</surname>
</string-name>, &#x0201c;<article-title>Comparative Analysis of Two Rates</article-title>,&#x0201d; <source>Statistics in Medicine</source>
<volume>4</volume>, no. <issue>2</issue> (<year>1985</year>): <fpage>213</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">4023479</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="pds70160-cit-0012">
<string-name>
<given-names>T. P.</given-names>
<surname>Morris</surname>
</string-name>, <string-name>
<given-names>I. R.</given-names>
<surname>White</surname>
</string-name>, and <string-name>
<given-names>M. J.</given-names>
<surname>Crowther</surname>
</string-name>, &#x0201c;<article-title>Using Simulation Studies to Evaluate Statistical Methods</article-title>,&#x0201d; <source>Statistics in Medicine</source>
<volume>38</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>2074</fpage>&#x02013;<lpage>2102</lpage>.<pub-id pub-id-type="pmid">30652356</pub-id>
</mixed-citation></ref><ref id="pds70160-bib-0013"><label>13</label><mixed-citation publication-type="book" id="pds70160-cit-0013">
<collab collab-type="authors">R Core Team</collab>
, <source>R: A Language and Environment for Statistical Computing</source> (<publisher-name>R Foundation for Statistical Computing</publisher-name>, <year>2024</year>).</mixed-citation></ref><ref id="pds70160-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="pds70160-cit-0014">
<string-name>
<given-names>K. S.</given-names>
<surname>Bae</surname>
</string-name>, <article-title>&#x0201c;sasLM: &#x0201c;SAS&#x0201d; Linear Model,&#x0201d; 2024</article-title>, <ext-link xlink:href="https://cran.r-project.org/package=sasLM" ext-link-type="uri">https://CRAN.R&#x02010;project.org/package=sasLM</ext-link>.</mixed-citation></ref><ref id="pds70160-bib-0015"><label>15</label><mixed-citation publication-type="miscellaneous" id="pds70160-cit-0015">
<string-name>
<given-names>L.</given-names>
<surname>Sun</surname>
</string-name>, <article-title>&#x0201c;ORCI,&#x0201d; 2014</article-title>, <ext-link xlink:href="https://cran.r-project.org/web/packages/ORCI/index.html" ext-link-type="uri">https://cran.r&#x02010;project.org/web/packages/ORCI/index.html</ext-link>.</mixed-citation></ref></ref-list><app-group><app id="pds70160-app-0001" content-type="Appendix"><label>Appendix 1</label><p>
<disp-formula id="pds70160-disp-0001">
<mml:math id="jats-math-2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>Var</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced close=")" open="("><mml:mi>SR</mml:mi></mml:mfenced></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mtext>Upper bound of the</mml:mtext><mml:mspace width="0.25em"/><mml:mn>95</mml:mn><mml:mo>%</mml:mo><mml:mi>CI</mml:mi></mml:mrow><mml:mrow><mml:mtext>Lower bound of the</mml:mtext><mml:mspace width="0.25em"/><mml:mn>95</mml:mn><mml:mo>%</mml:mo><mml:mi>CI</mml:mi></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>&#x000f7;</mml:mo><mml:mn>3.92</mml:mn></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math>
</disp-formula>where SR&#x02009;=&#x02009;sequence ratio, CI&#x02009;=&#x02009;compatibility interval.</p></app><app id="pds70160-app-0002" content-type="Appendix"><label>Appendix 2</label><p>
<disp-formula id="pds70160-disp-0002">
<mml:math id="jats-math-3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mn>95</mml:mn><mml:mo>%</mml:mo><mml:mi>CI</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mi>SR</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>SR</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac></mml:mfenced><mml:mo linebreak="goodbreak">&#x000b1;</mml:mo><mml:mn>1.96</mml:mn><mml:mo>&#x000b7;</mml:mo><mml:msqrt><mml:mrow><mml:mi>Var</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>SR</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>Var</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>SR</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</disp-formula>where SR&#x02009;=&#x02009;sequence ratio, CI&#x02009;=&#x02009;compatibility interval.</p></app><app id="pds70160-app-0003" content-type="Appendix"><label>Appendix 3</label><p>
<disp-formula id="pds70160-disp-0003">
<mml:math id="jats-math-4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>SE</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:msqrt><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>d</mml:mi></mml:mfrac></mml:mrow></mml:msqrt></mml:mrow></mml:mrow></mml:math>
</disp-formula>where <italic toggle="yes">a</italic>, <italic toggle="yes">b</italic>, <italic toggle="yes">c</italic>, and <italic toggle="yes">d</italic> correspond to the number of exposure&#x02010;to&#x02010;outcome and outcome&#x02010;to&#x02010;exposure sequences observed for the drug of interest and the comparator drug. SE = standard error.</p></app></app-group></back></article>